PharmaGap Completes Placement of Equity Units
October 21 2011 - 4:00PM
Marketwired
PharmaGap Inc. (TSX VENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the
Company") announced today the final closing of a private offering
of 2,190,000 equity units (the "Units") for a net aggregate amount
of $175,210, as conditionally closed on September 21, 2011, at a
price of $0.08 per Unit.
The conditional closing and details of this placement and the
Units were previously announced on September 21, 2011. TSX Venture
Exchange regulations require this announcement on final closing of
the placement.
The final closing of this private placement is subject to the
approval of the TSX Venture Exchange and the shares and warrants
issued pursuant to the private placement are restricted from
trading for four months from the date of the conditional
closing.
As previously announced, in connection with this closing,
$10,513 in cash fees and 131,400 broker warrants, issued on the
same terms and conditions as the warrants included in the Units,
were paid to individuals dealing at arm's length to PharmaGap.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is
a novel peptide drug that has been shown to be highly cytotoxic to
numerous cancer types, including chemo-resistant cancers, in vitro.
For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.
Forward Looking Statements
This news release contains certain statements that constitute
forward-looking statements as they relate to the Company and its
management. Forward-looking statements are not historical facts but
represent management's current expectations of future events, and
can be identified by words such as "believe", "expects", "will",
"intends", "plans", "projects", "anticipates", "estimates",
"continues", and similar expressions. Although management believes
that expectations represented in such forward-looking statements
are reasonable, there can be no assurance that they will prove to
be correct.
By their nature, forward-looking statements include assumptions
and are subject to inherent risks and uncertainties that could
cause actual future results, conditions, actions or events to
differ materially from those in the forward-looking statements. If
and when forward-looking statements are set out in this news
release, PharmaGap will also set out the material risk factors or
assumptions used to develop the forward-looking statements. Except
as expressly required by applicable securities laws, the Company
assumes no obligation to update or revise any forward-looking
statements. The future outcomes that relate to forward-looking
statements may be influenced by many factors, including, but not
limited to: results of ongoing product testing and development;
regulatory approvals required to complete development of products;
ability to manufacture product at quality and scale for human use
on an economically sound basis; patient reimbursement by private
and public health insurance programs; unintended side effects of
products; competitive products; product liability; intellectual
property; reliance on key personnel; risks of future legal
proceedings; income tax matters; availability and terms of
financing; distribution of securities; effect of market interest
rates on price of securities, and potential dilution.
Note: Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has
approved or disapproved of the information contained herein. This
release contains forward looking statements that may not occur or
may change materially.
Contacts: PharmaGap Inc. Robert McInnis President & CEO
(613) 990-9551bmcinnis@pharmagap.com
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Jun 2023 to Jun 2024